Exagen (XGN) Stock Price, News & Analysis

Company Overview

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Key Stats

• Today's Range: $3.52 to $3.96
• 50-Day Range: $3.00 to $6.00
• 52-Week Range: $1.30 to $6.22
• Volume: 54,849 shs
• Average Volume: 151,972 shs
• Market Capitalization: $63.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Buy

Exagen Stock Analysis - MarketRank™

Exagen scored higher than 86% of companies evaluated by MarketBeat, and ranked 74th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Exagen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Exagen are expected to grow in the coming year, from ($0.88) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exagen is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exagen is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exagen has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.30% of the float of Exagen has been sold short.

Short Interest Ratio / Days to Cover

Exagen has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exagen has recently increased by 260.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exagen does not currently pay a dividend.

Dividend Growth

Exagen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.29

Percentage of Shares Shorted

0.30% of the float of Exagen has been sold short.

Short Interest Ratio / Days to Cover

Exagen has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exagen has recently increased by 260.81%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for XGN on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

4 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.10% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XGN Stock Analysis - Frequently Asked Questions

How have XGN shares performed this year?

Exagen's stock was trading at $4.10 at the start of the year. Since then, XGN shares have decreased by 12.7% and is now trading at $3.58.
View the best growth stocks for 2025 here.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) issued its earnings results on Tuesday, November, 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. The company earned $12.51 million during the quarter, compared to analysts' expectations of $13.55 million. Exagen had a negative net margin of 30.36% and a negative trailing twelve-month return on equity of 92.58%.

When did Exagen IPO?

Exagen (XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

Who are Exagen's major shareholders?

Exagen's top institutional shareholders include Toronto Dominion Bank (5.05%), Toronto Dominion Bank (5.05%), Silvercrest Asset Management Group LLC (3.03%) and Perkins Capital Management Inc. (2.40%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, James L L Tullis, John Aballi, Kamal Adawi and Mark Hazeltine.
View institutional ownership trends.

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:XGN
• CUSIP: N/A
• CIK: 1274737
• Web: www.exagen.com
• Phone: 760-560-1501
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.50
• High Stock Price Target: $8.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +109.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,690,000.00
• Net Margins: -30.36%
• Pretax Margin: -30.30%
• Return on Equity: -92.58%
• Return on Assets: -33.74%

Debt

• Debt-to-Equity Ratio: 1.54
• Current Ratio: 4.05
• Quick Ratio: 4.05

Sales & Book Value

• Annual Sales: $52.55 million
• Price / Sales: 1.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.33 per share
• Price / Book: 2.69

Miscellaneous

• Outstanding Shares: 17,640,000
• Free Float: 13,034,000
• Market Cap: $63.15 million
• Optionable: Optionable
• Beta: 1.41